UTAH MEDICAL PRODUCTS INC

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

UTMD$72.86-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Cash Flow

UTAH MEDICAL PRODUCTS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOW
Years Ended December 31, 2025, 2024 and 2023
(In thousands)
2025 · 2024 · 2023
Cash flows from operating activities:
Net income		$11,286		$13,874		$16,635
Adjustments to reconcile net income to net
cash provided by operating activities:
		Depreciation		826		730		623
		Amortization		2,126		2,065		5,692
		Provision for losses on accounts receivable		367		(4)		(33)
		Amortization of operating lease assets		56		51		53
		Deferred income taxes		(659)		(359)		(693)
		Stock-based compensation expense		373		256		225
		Tax benefit attributable to exercise of stock options		-		21		12
(Increase) decrease in:
			Accounts receivable		338		(835)		2,270
			Other receivables		(5)		54		-
			Inventories		1,195		587		(670)
			Prepaid expenses and other current assets		(54)		(32)		45
Increase (decrease) in:
			Accounts payable		211		(73)		(456)
			Accrued expenses		(1,368)		(1,504)		(1,422)
				Net cash provided by operating activities		14,692		14,831		22,281
Cash flows from investing activities:
Capital expenditures for:
		Property and equipment		(371)		(230)		(639)
		Intangible assets		-		(5)		-
		Proceeds from the sale of property and equipment		-		27		-
				Net cash (used in) investing activities		(371)		(208)		(639)
Cash flows from financing activities:
	Proceeds from issuance of common stock - options		-		390		117
	Common stock purchased and retired		(8,355)		(19,968)		-
	Dividends paid		(3,983)		(4,260)		(4,282)
				Net cash (used in) financing activities		(12,338)		(23,838)		(4,165)
Effect of exchange rate changes on cash		797		(677)		339
				Net increase (decrease) in cash and cash equivalents		2,780		(9,892)		17,816
Cash at beginning of year		82,976		92,868		75,052
Cash at end of year		$85,756		$82,976		$92,868
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the year for:
	Income taxes		$4,003		$4,638		$4,827
Interest · - · - · -
See accompanying notes to financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.